Conference
Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
Authors
Sands BE; Moss AC; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Zeroncio M; Modesto I; Salese L
Volume
14
Pagination
pp. S110-S111
Publisher
OXFORD UNIV PRESS
Publication Date
January 1, 2020
Conference proceedings
JOURNAL OF CROHNS & COLITIS
ISSN
1873-9946